Assessment of the Potential Effect of S-Methylcysteine Alone and in Combination with Metal-Organic Framework Nanoparticles on Experimental Toxoplasmosis in Immunosuppressed Mice | ||
| Egyptian Journal of Veterinary Sciences | ||
| Articles in Press, Corrected Proof, Available Online from 16 October 2024 PDF (1.25 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejvs.2024.313962.2327 | ||
| Authors | ||
| Shaimaa helmy El-Sayed1; Ahmed Eassa2; Mousa Ismail2; Marwa Elmallawany2; Sara Abd Elhady* 3; Reda Abdelhameed4; Ashraf Mohamed Barakat5 | ||
| 1Medical Parasitology Department, Faculty of Medicine, Helwan University, Cairo, Egypt. | ||
| 2Department of Medical Parasitology, Faculty of Medicine, Cairo University, Egypt. | ||
| 3Medical parasitology department, faculty of medicine, Helwan university | ||
| 4Applied Organic Chemistry Department, National Research Centre, Giza, Egypt. | ||
| 5Department of Zoonotic Diseases, Veterinary Research Institute, National Research Centre, 33 Bohouth str. Dokki, Giza, Egypt | ||
| Abstract | ||
| This study was conducted to investigate the potential therapeutic effect of S-methylcysteine (SMC) used singly, in combination with pyrimethamine (P) and sulfadiazine (S) regimen, and in conjugation with metal-organic framework nanoparticles (MOFs) on chronic toxoplasmosis in immunosuppressed mice. Fifty-four mice were immunosuppressed and divided into 9 groups (G); GІ (negative control), GП (positive control), GⅢ- GⅣf (infected and treated); GⅢ (P-S), GⅣa (SMC50), GⅣb (SMC25), GⅣc (SMC25, P-S), GⅣd (SMC25-MOFs), GⅣe (SMC25, P-MOFs, and S-MOFs), and GⅣf (SMC25-MOFs, P-MOFs, and S-MOFs). The infected mice were orally inoculated with 20 Toxoplasma cysts/ mouse. Mice treatment stared Fifty days post infection for 10 consecutive days. Assessment of the therapeutic effect of each treatment model included: parasitological parameters (brain cyst burden), histopathological examination of mice brain sections, and immunological assessment of mice serum interferon gamma (IFN-Υ) levels. GⅣf exhibited the highest percentage of brain cyst reduction (70.54%) and the highest percentage of IFN-Υ levels increase (182.23%). Nevertheless, significant increase in glial cell number, an evident increase in the degree of inflammation. Drugs loaded on MOFs have anti-Toxoplasma effect on chronic toxoplasmosis in immunosuppressed mice. | ||
| Keywords | ||
| T. gondii; Pyrimethamine; Sulfadiazine; SMC; MOFs | ||
|
Statistics Article View: 357 PDF Download: 212 |
||